866-997-4948(US-Canada Toll Free)

Behcet Disease - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 80 Pages

Behcet Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease Pipeline Review, H2 2016, provides an overview of the Behcet Disease (Immunology) pipeline landscape.

Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Behcet Disease Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Behcet Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Behcet Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 3, 2, 1, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Behcet Disease.

Behcet Disease (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Behcet Disease (Immunology).
- The pipeline guide reviews pipeline therapeutics for Behcet Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Behcet Disease (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Behcet Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Behcet Disease (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Behcet Disease (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Behcet Disease (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Behcet Disease Overview 7
Therapeutics Development 8
Pipeline Products for Behcet Disease - Overview 8
Pipeline Products for Behcet Disease - Comparative Analysis 9
Behcet Disease - Therapeutics under Development by Companies 10
Behcet Disease - Therapeutics under Investigation by Universities/Institutes 11
Behcet Disease - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Behcet Disease - Products under Development by Companies 16
Behcet Disease - Products under Investigation by Universities/Institutes 17
Behcet Disease - Companies Involved in Therapeutics Development 18
AbbVie Inc 18
Celgene Corp 19
Cell Medica Ltd 20
Coherus BioSciences Inc 21
Genor BioPharma Co Ltd 22
Iltoo Pharma 23
Mycenax Biotech Inc 24
Novartis AG 25
Panacea Biotec Ltd 26
R Pharm 27
Behcet Disease - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
adalimumab - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
adalimumab biosimilar - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
adalimumab biosimilar - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
adalimumab biosimilar - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
adalimumab biosimilar - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
aldesleukin - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
apremilast - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
canakinumab - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
DLX-105 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
infliximab biosimilar - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
pentoxifylline - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
RPH-104 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Behcet Disease - Dormant Projects 72
Behcet Disease - Discontinued Products 73
Behcet Disease - Product Development Milestones 74
Featured News & Press Releases 74
Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir 74
Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet 75
Apr 15, 2015: Phase II Data for Apremilast in Behcets Disease Published in The New England Journal of Medicine 75
Apr 14, 2015: Delenex Announces New Clinical Data 77
Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behcets Disease At EULAR 77
May 24, 2013: AbbVie And Eisai Receive Indication Approval For Treatment Of Intestinal Behcet Disease For Humira Pre-filled Syringe In Japan 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables
Number of Products under Development for Behcet Disease, H2 2016 8
Number of Products under Development for Behcet Disease - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Comparative Analysis by Unknown Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Behcet Disease - Pipeline by AbbVie Inc, H2 2016 18
Behcet Disease - Pipeline by Celgene Corp, H2 2016 19
Behcet Disease - Pipeline by Cell Medica Ltd, H2 2016 20
Behcet Disease - Pipeline by Coherus BioSciences Inc, H2 2016 21
Behcet Disease - Pipeline by Genor BioPharma Co Ltd, H2 2016 22
Behcet Disease - Pipeline by Iltoo Pharma, H2 2016 23
Behcet Disease - Pipeline by Mycenax Biotech Inc, H2 2016 24
Behcet Disease - Pipeline by Novartis AG, H2 2016 25
Behcet Disease - Pipeline by Panacea Biotec Ltd, H2 2016 26
Behcet Disease - Pipeline by R Pharm, H2 2016 27
Assessment by Monotherapy Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Behcet Disease - Dormant Projects, H2 2016 72
Behcet Disease - Discontinued Products, H2 2016 73

List of Figures
Number of Products under Development for Behcet Disease, H2 2016 8
Number of Products under Development for Behcet Disease - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 28
Number of Products by Targets, H2 2016 29
Number of Products by Stage and Targets, H2 2016 29
Number of Products by Mechanism of Actions, H2 2016 31
Number of Products by Stage and Mechanism of Actions, H2 2016 31
Number of Products by Routes of Administration, H2 2016 33
Number of Products by Stage and Routes of Administration, H2 2016 33
Number of Products by Molecule Types, H2 2016 35
Number of Products by Stage and Molecule Types, H2 2016 35

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *